Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Gene Mutation”

267 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 267 results

Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Large-scale testing (Phase 3)Looking for participantsNCT07491445
What this trial is testing

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more
Revolution Medicines, Inc. 900
Early research (Phase 1)Looking for participantsNCT06179160
What this trial is testing

Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Incyte Corporation 710
Testing effectiveness (Phase 2)Looking for participantsNCT06667544
What this trial is testing

RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Who this might be right for
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd. 152
Early research (Phase 1)Looking for participantsNCT06227377
What this trial is testing

QTX3034 in Patients With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Quanta Therapeutics 250
Testing effectiveness (Phase 2)UnknownNCT06237413
What this trial is testing

ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Who this might be right for
Solid TumorKRAS Mutation-Related Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 110
Not applicableStudy completedNCT04287335
What this trial is testing

Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China

Who this might be right for
Colorectal CancerAdenomatous PolypsAdenoma+1 more
Zhejiang University 4,758
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Testing effectiveness (Phase 2)Study completedNCT03704688
What this trial is testing

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Gene Mutation
Memorial Sloan Kettering Cancer Center 12
Large-scale testing (Phase 3)Looking for participantsNCT06416410
What this trial is testing

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Who this might be right for
Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 392
Not applicableStudy completedNCT01700582
What this trial is testing

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Who this might be right for
Carcinoma, Non-Small-Cell LungALK Gene MutationKRAS Gene Mutation+1 more
Intergroupe Francophone de Cancerologie Thoracique 17,664
Testing effectiveness (Phase 2)WithdrawnNCT05815186
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health
Testing effectiveness (Phase 2)Study completedNCT03520842
What this trial is testing

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Who this might be right for
KRAS Gene MutationMetastatic Malignant Neoplasm in the BrainRecurrent Non-Small Cell Lung Carcinoma+1 more
Stanford University 22
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Testing effectiveness (Phase 2)Looking for participantsNCT07438106
What this trial is testing

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Who this might be right for
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University 30
Testing effectiveness (Phase 2)UnknownNCT04010552
What this trial is testing

Nalirinox Neo-pancreas RAS Mut ctDNA Study

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma
Fundación de investigación HM 20
Load More Results
110